https://www.bioqubeventures.com/news/ 2026-11-04T09:38:49+00:00 https://www.bioqubeventures.com/spica-therapeutics-secures-1-million-vlaio-grant/ 2025-10-06T12:55:54+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Spica.png https://www.bioqubeventures.com/commit-biologics-appoints-leading-industry-experts/ 2025-10-06T12:57:22+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/commit-biologics.png https://www.bioqubeventures.com/egle-therapeutics-to-present-new-preclinical-data-egl-003/ 2025-10-06T12:57:27+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Egle-Therapeutics.jpg https://www.bioqubeventures.com/spica-therapeutics-closes-10-million-seed-round/ 2025-10-06T12:57:52+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Spica.png https://www.bioqubeventures.com/egle-therapeutics-to-present-clinical-trial-progress/ 2025-10-06T12:58:21+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Egle-Therapeutics.jpg https://www.bioqubeventures.com/egle-therapeutics-to-highlight-novel-preclinical-findings-for-regulatory-t-cells/ 2025-10-06T12:59:03+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Egle-Therapeutics.jpg https://www.bioqubeventures.com/egle-therapeutics-receives-9-3-million-in-state-funding/ 2025-10-06T12:59:52+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Egle-Therapeutics.jpg https://www.bioqubeventures.com/commit-biologics-announces-5-5m-seed-financing-extension-investment/ 2025-10-06T13:00:14+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/commit-biologics.png https://www.bioqubeventures.com/egle-therapeutics-strengthens-its-executive-leadership-team/ 2025-10-06T13:00:32+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Egle-Therapeutics.jpg https://www.bioqubeventures.com/bioqube-ventures-unveils-spica-therapeutics-to-pioneer-macrophage-subset-targeted-therapies/ 2025-10-06T13:01:07+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/logo-bioqube@4x.webp https://www.bioqubeventures.com/commit-biologics-appoints-mikkel-wandah/ 2025-10-06T13:02:44+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/commit-biologics.png https://www.bioqubeventures.com/bicara-therapeutics-reports-updated-interim-phase/ 2025-10-06T13:06:44+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Bicara-Therapeutics.jpg https://www.bioqubeventures.com/enhanc3d-genomics-appoints-hazel-jones/ 2025-10-06T13:07:14+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Enhanc3D-Genomics.png https://www.bioqubeventures.com/egle-therapeutics-strengthens-its-leadership-team/ 2025-10-06T13:07:34+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Egle-Therapeutics.jpg https://www.bioqubeventures.com/commit-biologics-launches-with-16m-seed-financing/ 2025-10-06T13:08:10+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/commit-biologics.png https://www.bioqubeventures.com/egle-therapeutics-to-present-novel-immunocytokine-preclinical-data/ 2025-10-06T13:08:57+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Egle-Therapeutics.jpg https://www.bioqubeventures.com/bicara-therapeutics-expands-clinical-team/ 2025-10-06T13:09:18+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Bicara-Therapeutics.jpg https://www.bioqubeventures.com/primmune-therapeutics-secures-22-5-million-contract/ 2025-10-06T13:09:44+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Primmune-Therapeutics.png https://www.bioqubeventures.com/enhanc3d-genomics-appoints-dr-daniel-turner-as-chief-scientific-officer/ 2025-10-06T13:10:04+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Enhanc3D-Genomics.png https://www.bioqubeventures.com/bicara-therapeutics-announces-oversubscribed-165-million-series-c-financing/ 2025-10-06T13:10:28+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Bicara-Therapeutics.jpg https://www.bioqubeventures.com/bicara-therapeutics-presents-updated-interim-data/ 2025-10-06T13:10:48+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Bicara-Therapeutics.jpg https://www.bioqubeventures.com/bicara-therapeutics-expands-board-of-directors-3/ 2025-10-06T13:11:08+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Bicara-Therapeutics.jpg https://www.bioqubeventures.com/primmune-therapeutics-to-present-new-clinical-data/ 2025-10-06T13:11:38+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Primmune-Therapeutics.png https://www.bioqubeventures.com/anavo-therapeutics-strengthens-management-team/ 2025-10-06T13:11:59+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Anavo-Therapeutics.png https://www.bioqubeventures.com/bicara-therapeutics-expands-management-team/ 2025-10-06T13:12:18+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Bicara-Therapeutics.jpg https://www.bioqubeventures.com/bicara-therapeutics-first-in-class-bifunctional-egfr-tgf-%ce%b2-inhibitor-bca101/ 2025-10-06T13:12:52+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Bicara-Therapeutics.jpg https://www.bioqubeventures.com/anavo-therapeutics-extends-seed-round-to-eur-28-million/ 2025-10-06T13:13:14+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Anavo-Therapeutics.png https://www.bioqubeventures.com/primmune-therapeutics-presents-new-clinical-data-from-phase-1-study/ 2025-10-06T13:13:44+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Primmune-Therapeutics.png https://www.bioqubeventures.com/primmune-therapeutics-to-present-new-clinical-data-2/ 2025-10-06T13:14:03+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Primmune-Therapeutics.png https://www.bioqubeventures.com/bicara-therapeutics-announces-oversubscribed-108-million-series-b-financing/ 2025-10-06T13:14:33+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Bicara-Therapeutics.jpg https://www.bioqubeventures.com/enhanc3d-genomics-raises-10-million-in-series-a-financing/ 2025-10-06T13:16:28+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Enhanc3D-Genomics.png https://www.bioqubeventures.com/tridek-one-closes-a-16-million-financing-round/ 2025-10-06T13:16:50+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/tridek-one.png https://www.bioqubeventures.com/enhanc3d-genomics-awarded-quickfire-challenge-grant/ 2025-10-06T13:17:19+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Enhanc3D-Genomics.png https://www.bioqubeventures.com/primmune-therapeutics-receives-8-4-million/ 2025-10-06T13:18:11+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Primmune-Therapeutics.png https://www.bioqubeventures.com/primmune-therapeutics-provides-update-on-phase-1-healthy-volunteer/ 2025-10-06T13:18:40+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Primmune-Therapeutics.png https://www.bioqubeventures.com/anavo-therapeutics-to-establish-rd-hub/ 2025-10-06T13:19:00+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Anavo-Therapeutics.png https://www.bioqubeventures.com/egle-therapeutics-raises-40-million-series-a/ 2025-10-06T13:19:28+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Egle-Therapeutics.jpg https://www.bioqubeventures.com/anavo-therapeutics-strengthens-scientific-advisory-board/ 2025-10-06T13:19:45+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Anavo-Therapeutics.png https://www.bioqubeventures.com/anavo-therapeutics-launches-with-eur-20-million-seed-financing/ 2025-10-06T13:20:10+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Anavo-Therapeutics.png https://www.bioqubeventures.com/primmune-therapeutics-strengthens-leadership-team/ 2025-10-06T13:20:32+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Primmune-Therapeutics.png https://www.bioqubeventures.com/primmune-therapeutics-announces-close-of-series-a-financing/ 2025-10-06T13:20:50+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Primmune-Therapeutics.png https://www.bioqubeventures.com/lonza-and-bioqube-ventures-sign-a-framework-agreement/ 2025-10-09T09:54:11+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/logo-bioqube@4x.webp https://www.bioqubeventures.com/bioqube-ventures-welcomes-two-seasoned-professionals/ 2025-10-09T09:55:14+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/logo-bioqube@4x.webp https://www.bioqubeventures.com//www/wp-content/uploads/2020/06/EIF-logo-2.png https://www.bioqubeventures.com//www/wp-content/uploads/2020/06/EC-logo-1.png https://www.bioqubeventures.com//www/wp-content/uploads/2020/06/BFF-logo-1.png https://www.bioqubeventures.com//www/wp-content/uploads/2020/06/BQV-logo-1.png https://www.bioqubeventures.com/bioqube-ventures-launches-bioqube-factory-fund-i/ 2025-10-09T09:55:33+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/logo-bioqube@4x.webp https://www.bioqubeventures.com//www/wp-content/uploads/2020/06/EIF-logo-2.png https://www.bioqubeventures.com//www/wp-content/uploads/2020/06/EC-logo-1.png https://www.bioqubeventures.com//www/wp-content/uploads/2020/06/BQV-logo-1.png https://www.bioqubeventures.com//www/wp-content/uploads/2020/06/BFF-logo-1.png https://www.bioqubeventures.com/commit-biologics-appoints-accomplished-rd-executive-to-its-board/ 2025-10-11T12:05:46+00:00 https://www.bioqubeventures.com/wp-content/uploads/2024/10/commit-biologics-update.webp https://www.bioqubeventures.com/synox-therapeutics-receives-fast-track-designation-for-emactuzumab-for-tenosynovial-giant-cell-tumours-tgct/ 2025-10-11T12:16:58+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/04/synox-therapeutics-update3.webp https://www.bioqubeventures.com/synox-therapeutics-announces-board-chair-transition/ 2025-10-11T12:18:42+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/04/synox-therapeutics-update3.webp https://www.bioqubeventures.com/synox-therapeutics-secures-up-to-35m-debt-financing/ 2025-10-11T12:19:11+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/04/synox-therapeutics-update3.webp https://www.bioqubeventures.com/catalym-to-present-new-data/ 2025-10-11T12:20:35+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/10/CatalYm_Start-Up-im-IZB-update.webp https://www.bioqubeventures.com/catalym-leadership-changes/ 2025-10-11T12:21:02+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/10/CatalYm_Start-Up-im-IZB-update.webp https://www.bioqubeventures.com/catalym-appoints-scott-clarke-ceo/ 2025-10-11T12:21:43+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/10/CatalYm_Start-Up-im-IZB-update.webp https://www.bioqubeventures.com/catalym-announces-new-financing-of-150m/ 2025-10-11T12:22:31+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/10/CatalYm_Start-Up-im-IZB-update.webp https://www.bioqubeventures.com/actithera-raises-75-5m/ 2025-10-11T13:17:24+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/actithera.webp https://www.bioqubeventures.com/synox-therapeutics-adds-new-investor-and-capital/ 2025-10-11T16:06:48+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/04/synox-therapeutics-update3.webp https://www.bioqubeventures.com/synox-therapeutics-completes-enrollment-in-registrational-phase-3/ 2025-10-11T16:10:36+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/04/synox-therapeutics-update3.webp https://www.bioqubeventures.com/wp-content/uploads/2025/07/Synox.webp https://www.bioqubeventures.com/synox-therapeutics-announces-75m-series-b-round/ 2025-10-11T16:11:14+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/04/synox-therapeutics-update3.webp https://www.bioqubeventures.com/bicara-therapeutics-expands-board-of-directors/ 2025-10-16T12:10:00+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Bicara-Therapeutics.jpg https://www.bioqubeventures.com/bicara-therapeutics-announces-closing-of-362-million-initial-public-offering/ 2025-10-16T12:11:06+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Bicara-Therapeutics.jpg https://www.bioqubeventures.com/anavo-therapeutics-appoints-dr-edward-holson/ 2025-10-16T12:23:51+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Anavo-Therapeutics.png https://www.bioqubeventures.com/synox-therapeutics-strengthens-board-of-directors-with-leading-experts-in-commercialisation-and-corporate-development-amid-continued-corporate-progress/ 2025-11-30T15:05:05+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/04/synox-therapeutics-update3.webp https://www.bioqubeventures.com/bicara-therapeutics-announces-ficerafusp-alfa-granted-breakthrough-therapy-designation-by-u-s-fda-for-1l-hpv-negative-r-m-hnscc/ 2025-12-01T14:59:28+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Bicara-Therapeutics.jpg https://www.bioqubeventures.com/catalym-presents-long-term-phase-1-2a-data-confirming-sustained-responses-with-visugromab-in-cpi-refractory-tumors-at-esmo-2025/ 2025-12-01T15:06:44+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/10/CatalYm_Start-Up-im-IZB-update.webp https://www.bioqubeventures.com/catalym-presents-phase-2-data-in-neoadjuvant-bladder-cancer-demonstrating-substantial-increase-of-anti-tumor-activity-for-visugromab-in-combination-with-pd-1-inhibitor-at-esmo/ 2025-12-01T15:08:04+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/10/CatalYm_Start-Up-im-IZB-update.webp https://www.bioqubeventures.com/catalym-announces-first-patient-dosed-in-phase-2b-trial-evaluating-visugromab-in-combination-with-chemoimmunotherapy-as-first-line-treatment-in-metastatic-non-squamous-nsclc/ 2025-12-01T15:10:03+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/10/CatalYm_Start-Up-im-IZB-update.webp https://www.bioqubeventures.com/bioqube-ventures-appoints-tom-heyman-executive-partner/ 2026-01-28T09:09:55+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/logo-bioqube@4x.webp https://www.bioqubeventures.com/primmune-therapeutics-additional-close-series-b-financing/ 2026-02-07T14:50:15+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Primmune-Therapeutics.png https://www.bioqubeventures.com/primmune-therapeutics-appoints-chief-medical-officer-and-executive-board-chair/ 2026-02-07T14:58:32+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/Primmune-Therapeutics.png https://www.bioqubeventures.com/bioqube-ventures-strengthens-leadership-team-with-the-appointment-of-tessa-ceyssens-as-chief-operating-officer/ 2026-02-07T15:01:32+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/logo-bioqube@4x.webp https://www.bioqubeventures.com/wp-content/uploads/2026/01/Tessa_Ceyssens-300x300.webp https://www.bioqubeventures.com/synox-therapeutics-announces-positive-topline-results-from-the-phase-3-tangent-study-supporting-emactuzumab-as-a-differentiated-next-generation-treatment-for-patients-with-tenosynovial-giant-cell-tu/ 2026-04-13T06:29:32+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/04/synox-therapeutics-update3.webp https://www.bioqubeventures.com/catalym-advances-visugromab-into-phase-2-3-development-for-cancer-cachexia-with-first-patient-dosed/ 2026-04-23T13:27:08+00:00 https://www.bioqubeventures.com/wp-content/uploads/2026/04/CatalYm_Start-Up-im-IZB-update.webp https://www.bioqubeventures.com/catalym-doses-first-patient-in-phase-2b-trial-evaluating-visugromab-in-combination-with-chemoimmunotherapy-as-second-line-treatment-in-unresectable-metastatic-hepatocellular-carcinoma/ 2026-04-23T13:28:03+00:00 https://www.bioqubeventures.com/wp-content/uploads/2026/04/CatalYm_Start-Up-im-IZB-update.webp https://www.bioqubeventures.com/catalym-appoints-christian-s-schade-as-chairman-of-the-board-of-directors/ 2026-04-28T12:58:25+00:00 https://www.bioqubeventures.com/wp-content/uploads/2026/04/CatalYm_Start-Up-im-IZB-update.webp https://www.bioqubeventures.com/bioqube-welcomes-bonnie-van-wilgenburg-as-venture-partner/ 2026-09-23T16:10:19+00:00 https://www.bioqubeventures.com/wp-content/uploads/2025/09/logo-bioqube@4x.webp https://www.bioqubeventures.com/primmune-therapeutics-announces-enrollment-milestone-in-phase-2-inflection-003-study-of-polvitolimod-hcl-in-neoadjuvant-melanoma/ 2026-09-29T05:30:24+00:00 https://www.bioqubeventures.com/actithera-significantly-strengthens-leadership-team-and-board-as-company-advances-towards-clinical-development/ 2026-09-29T07:19:38+00:00 https://www.bioqubeventures.com/catalym-appoints-peter-garcia-as-chief-financial-officer/ 2026-10-05T08:49:29+00:00 https://www.bioqubeventures.com/spica-therapeutics-appoints-jeff-abbey-as-chief-executive-officer/ 2026-10-06T05:51:34+00:00 https://www.bioqubeventures.com/catalym-presents-phase-2-data-showing-visugromab-substantially-enhances-the-clinical-benefit-of-pd-1-inhibition-in-neoadjuvant-bladder-cancer-at-esmo-2026/ 2026-10-26T08:33:23+00:00 https://www.bioqubeventures.com/primmune-therapeutics-to-present-prtx007-phase-1-pharmacology-and-phase-2-inflection-003-study-design-at-the-sitc-41st-annual-meeting/ 2026-11-04T09:38:49+00:00